P2.18-04 Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso)

This article has no abstract
Epistemonikos ID: d09ea8ba4902e738edc6bb169da7abcd61946022
First added on: Feb 16, 2025